动态监测D-二聚体在肿瘤患者导管相关性血栓的临床意义

doi:10.11904/j.issn.1002-3070.2019.05.008

摘要/Abstract

摘要： 目的探讨D-二聚体水平与肿瘤患者导管相关性血栓(Catheter related thrombosis,CRT)发生的相关性。方法对100例住院的深静脉置管肿瘤患者进行前瞻性研究,动态监测血浆D-二聚体以及静脉多普勒超声检查,观察CRT的发生率、发生时间及血栓类型等。结果 CRT的发生率为12.6%,其中无症状血栓占83.3%。58.3%的血栓发生在置管后2周内,91.7%发生在置管后的置管后4周内。置管后2周血栓组D-二聚体水平显著高于非血栓组(P=0.013)。结论肿瘤患者CRT大部分形成于深静脉置管后4周内,其中无症状性血栓的比例高,动态监测D-二聚体可能有助于其早期诊断。

关键词: D-二聚体, 肿瘤, 导管相关性血栓

Abstract: Objective The objective of this study was to investigate the correlation between D-dimer levels and the occurrence of catheter related thrombosis(CRT)in tumor patients.Methods A prospective study was performed on 100 cancer patients with deep venous catheterization.The plasma D-dimer and intravenous Doppler ultrasonography were used to observe the incidence,time and thrombus type of CRT.Results The incidence of CRT was 12.6%,and asymptomatic thrombosis accounted for 83.3%.58.3% of the thrombosis occurred within 2 weeks after catheterization,and 91.7% occurred within 4 weeks after catheterization.After 2 weeks of catheterization,the level of D-dimer in the thrombosis group was significantly higher than that in the non-thrombosis group(P=0.013).Conclusion Most of the CRT in tumor patients is formed within 4 weeks after deep venous catheterization.The proportion of asymptomatic thrombus is high,and dynamic monitoring of D-dimer may be helpful for early diagnosis.

Key words: D-dimer, Cancer, Catheter related thrombosis

中图分类号:

R730.6

杨敏, 谢俊英, 谭培昭, 吴晓明, 于雷. 动态监测D-二聚体在肿瘤患者导管相关性血栓的临床意义[J]. 实用肿瘤学杂志, 2019, 33(5): 425-430.

YANG Min, XIE Junying, TAN Peizhao, WU Xiaoming, YU Lei. Clinical significance of dynamic monitoring of D-dimer in catheter related thrombosis of cancer patients[J]. Journal of Practical Oncology, 2019, 33(5): 425-430.

0
/ / 推荐

导出引用管理器 EndNote|Reference Manager|ProCite|BibTeX|RefWorks

链接本文: http://journal09.magtechjournal.com/Jwk3_syzlxzz/CN/10.11904/j.issn.1002-3070.2019.05.008

http://journal09.magtechjournal.com/Jwk3_syzlxzz/CN/Y2019/V33/I5/425

参考文献

1 Verso M,Agnelli G.Venous thromboembolism associated with long-term use of central venous catheters in cancer patients[J].J Clin Oncol,2003,21(19):3665-3675.
2 Lee AY,Levine MN,Butler G,et al.Incidence,risk factors,and outcomes of catheter-related thrombosis in adult patients with cancer[J].J Clin Oncol,2006,24(9):1404-1408.
3 Khorana AA,Francis CW,Culakova E,et al.Frequency,risk factors,and trends for venous thromboembolism among hospitalized cancer patients[J].Cancer,2007,110(10):2339-2346.
4 Murray J,Precious E,Alikhan R.Catheter-related thrombosis in cancer patients[J].Br J Haematol,2013,162(6):748-757.
5 Lee KW,Bang SM,Kim S,et al.The incidence,risk factors and prognostic implications of venous thromboembolism in patients with gastric cancer[J].J Thromb Haemost,2010,8(3):540-547.
6 Lyman GH,Bohlke K,Falanga A,et al.Venous thromboembolism prophylaxis and treatment in patients with cancer:American Society of Clinical Oncology clinical practice guideline update[J].J Oncol Pract,2015,11(3):442-444.
7 Mandalà M,Falanga A,Roila F,et al.Management of venous thromboembolism(VTE)in cancer patients:ESMO clinical practice guidelines[J].Ann Oncol,2011,22(Suppl 6):85-92.
8 Kearon C,Akl EA,Ornelas J,et al.Antithrombotic therapy for VTE disease:CHEST Guideline and Expert Panel Report[J].Chest,2016,149(2):315-352.
9 Farge D,Bounameaux H,Brenner B,et al.International clinical practice guidelines including guidance for direct oral anticoagulants in the treatment and prophylaxis of venous thromboembolism in patients with cancer[J].Lancet Oncol,2016,17(10):452-466.
10 Riondino S,Ferroni P,Zanzotto FM,et al.Predicting VTE in cancer patients:candidate biomarkers and risk assessment models[J].Cancers(Basel),2019,11(1):95.
11 Debourdeau P,Espié M,Chevret S,et al.Incidence,risk factors,and outcomes of central venous catheter-related thromboembolism in breast cancer patients:the CAVECCAS study[J].Cancer Medicine,2017,6(11):2732-2744.
12 Nañez-Terreros H,Jaime-Perez JC,Muñoz-Espinoza LE,et al.D-dimer from central and peripheral blood samples in asymptomatic central venous catheter-related thrombosis in patients with cancer[J].Phlebology,2019,34(1):52-57.
13 Jansen FH,van der Straaten HM,Roest M,et al.Elevated levels of D-dimer and fragment 1+2 upon central venous catheter insertion and factor V Leiden predict subclavian vein thrombosis[J].Haematologica,2005,90(4):499-504.
14 Ferroni P,Martini F,Portarena I,et al.Novel high-sensitive D-dimer determination predicts chemotherapy-associated venous thromboembolism in intermediate risk lung cancer patients[J].Clin Lung Cancer,2012,13(6):482-487.
15 Kondo S,Sasaki M,Hosoi H,et al.Incidence and risk factors for venous thromboembolism in patients with pretreated advanced pancreatic carcinoma[J].Oncotarget,2018,9(24):16883-16890.
16 Park K,Ryoo BY,Ryu MH,et al.Incidence of venous thromboembolism and the role of D-dimer as predictive marker in patients with advanced gastric cancer receiving chemotherapy:A prospective study[J].World J Gastrointest Oncol,2017,15;9(4):176-183.
17 Evans RS,Sharp JH,Linford LH,et al.Risk of symptomatic DVT associated with peripherally inserted central catheters[J].Chest,2010,138(4):803-810.
18 Di Nisio M,Lee AYY,Carrier M,et al.Diagnosis and treatment of incidental venous thromboembolism in cancer patients:Guidance from the SSC of the ISTH[J].J Thromb Haemost,2015,13(5):880-883.
19 Gary T,Belaj K,Steidl K,et al.Asymptomatic deep vein thrombosis and superficial vein thrombosis in ambulatory cancer patients:impact on short-term survival[J].Br J Cancer,2012,107(8):1244-1248.
20 Font C,Farrús B,Vidal L,et al.Incidental versus symptomatic venous thrombosis in cancer:a prospective observational study of 340 consecutive patients[J].Ann Oncol,2011,22(9):2101-2106.
21 Bozkaya Y,Ozdemir N,Demirci NS,et al.Prognostic Effect of symptomatic and asymptomatic venous thromboembolism in patients with gastric cancer[J].Uluslararasi Hematoloji-Onkoloji Dergisi,2017,27(2):100-109.
22 Boddi M,Villa G,Chiostri M,et al.Incidence of ultrasound-detected asymptomatic long-term central vein catheter-related thrombosis and fibrin sheath in cancer patients[J].Eur J Haematol,2015,95(5):472-479.
23 Liu Y,Gao Y,Wei L,et al.Peripherally inserted central catheter thrombosis incidence and risk factors in cancer patients:a double-center prospective investigation[J].Ther Clin Risk Manag,2015,11:153-160.
24 Walshe LJ,Malak SF,Eagan J,et al.Complication rates among cancer patients with peripherally inserted central catheters[J].J Clin Oncol,2002,20(15):3276-3281.

[1]	夏天一, 张博淼, 姚克非, 崔滨滨. PTPN9表达水平与结直肠癌的临床关系研究[J]. 实用肿瘤学杂志, 2019, 33(5): 415-419.
[2]	黄显博, 史庭 , 叶琇锦. 靶向PI3K/AKT/mTOR信号通路治疗急性T淋巴细胞白血病的研究进展[J]. 实用肿瘤学杂志, 2019, 33(5): 451-455.
[3]	李亚飞, 张霄, 王雪飞, 翁明娇, 王天真. RNA结合蛋白Lin28在恶性肿瘤发生发展中的作用和分子机制[J]. 实用肿瘤学杂志, 2019, 33(5): 456-460.
[4]	王宇, 乔娟娟, 张磊, 刘四卫 , 杨树才. 类固醇激素在乳腺癌中的作用及对肿瘤干细胞的影响[J]. 实用肿瘤学杂志, 2019, 33(5): 466-470.
[5]	陈宏博, 余增荣, 丁小凡肖林. 盆腔肿瘤IMRT下骨髓剂量-体积参数与急性血液学毒性相关性研究进展[J]. 实用肿瘤学杂志, 2019, 33(4): 361-366.
[6]	赵金璐, 李国东刘明. 长链非编码RNA CCAT1与消化系统恶性肿瘤关系的研究进展[J]. 实用肿瘤学杂志, 2019, 33(4): 367-370.
[7]	孙力超,杨婧,孙立新,张媛,杨治华,冉宇靓. 采用肝癌球体细胞筛选鉴定识别肝癌干细胞的单抗[J]. 实用肿瘤学杂志, 2019, 33(3): 193-199.
[8]	张佳文,于雁,张薇,曹京燕,罗雯,尚利华. 基于UPLC-TOF/MS的小细胞肺癌患者血清代谢组学研究[J]. 实用肿瘤学杂志, 2019, 33(3): 200-205.
[9]	张茂祥,孙惠昕,宋冰冰. 2008—2012年哈尔滨市道里区恶性肿瘤发病与死亡分析[J]. 实用肿瘤学杂志, 2019, 33(3): 261-265.
[10]	刘乙澍,曲国蕃. 长链非编码RNA在骨肉瘤中的研究进展[J]. 实用肿瘤学杂志, 2019, 33(3): 266-270.
[11]	侯玉雪,李晓莉. Wnt7a与恶性肿瘤的关系及研究进展[J]. 实用肿瘤学杂志, 2019, 33(3): 271-275.
[12]	朱琳,张春霞. 纳米载药系统靶向肿瘤干细胞的研究进展[J]. 实用肿瘤学杂志, 2019, 33(3): 276-279.
[13]	徐晖, 李希, 周春水. 应用以人转录组为靶点的shRNA文库筛选肺癌肿瘤相关抑制基因[J]. 实用肿瘤学杂志, 2019, 33(2): 97-102.
[14]	李诚, 兰莉, 杨超, 张婷婷, 王蕊, 林琳, 田文静. 2015—2017年哈尔滨市恶性肿瘤发病与死亡特征分析[J]. 实用肿瘤学杂志, 2019, 33(1): 62-66.
[15]	丁界先, 张津, 陈永刚, 王兴文综述, 王栓科审校. Wnt信号通路与肿瘤发生的研究进展[J]. 实用肿瘤学杂志, 2019, 33(1): 73-77.